Table 3.
The participants’ characteristics between those with and without adverse events (AEs) to the COVID-19 vaccine
| Parameter | Vaccinated Egyptian Rheumatologists (n = 200) | ||
|---|---|---|---|
| AE (n = 164) |
No. AE (n = 36) |
p | |
| Age (years) | 37.7 ± 8.1 | 40.8 ± 10.5 | 0.1 |
| Gender Female: male | 6.5:1 | 2.6:1 | 0.08 |
| Affiliation practice | |||
| University hospitals | 107 (65.2) | 29 (80.6) | 0.05 |
| Teaching hospitals | 16 (9.8) | 3 (8.3) | 0.79 |
| MOH | 36 (22) | 4 (11.1) | 0.09 |
| Private practice | 21 (12.8) | 8 (22.2) | 0.22 |
| Armed forces | 2 (1.2) | 1 (2.8) | 0.6 |
| Co-morbidity | |||
| Diabetes mellitus | 7 (4.3) | 3 (8.3) | 0.41 |
| Hypertension | 17 (10.4) | 4 (11.1) | 0.9 |
| Obesity | 15 (9.1) | 0 (0) | – |
| Thyroid dysfunction | 7 (4.3) | 1 (2.8) | 0.64 |
| Musculoskeletal | 9 (5.5) | 0 (0) | – |
| MS/dyslipidemia/cancer | 0 (0) | 1 (2.8) | – |
| FMF/APS/Ps/CV/IBS/atopy/sinusitis | 1 (0.6) | 0 (0) | – |
| Chest disease | 3 (1.8) | 1 (2.8) | 0.75 |
| Previous COVID-19 (anytime) | 112 (68.3) | 20 (55.6) | 0.17 |
| Once | 80 (48.8) | 17 (47.2) | 0.87 |
| Twice | 30 (18.3) | 3 (8.3) | 0.08 |
| Thrice | 2 (1.2) | 0 (0) | – |
| Type of vaccine | |||
| ChAdOx1 (AstraZeneca) | 82 (50) | 7 (19.4) | <0.0001 |
| BNT162 (Pfizer BioNTech) | 25 (15.2) | 2 (5.6) | 0.046 |
| Ad26.COV2-S (Johnson & Johnson) | 11 (6.7) | 5 (13.9) | 0.25 |
| mRNA1273 (Moderna) | 4 (2.4) | 0 (0) | 0.045 |
| BBIBP-CorV (Sinopharm) | 33 (20.1) | 17 (47.2) | 0.004 |
| CoronaVac (Sinovac) | 15 (9.1) | 6 (16.7) | 0.27 |
| Sputnik V (Gamaleya) | 4 (2.4) | 0 (0) | 0.045 |
| Post-vaccine COVID-19 infection | 25 (15.2) | 5 (13.9) | 0.84 |
AE adverse events, MOH ministry of health, MS multiple sclerosis, FMF familial Mediterranean fever, APS anti-phospholipid syndrome, Ps psoriasis, CV cardiovascular, IBS inflammatory bowel syndrome, COVID-19 coronavirus disease 2019
Bold values are significant at p < 0.05